Please note: Medicare Rebate for this test is subject to conditions. Patients may receive an invoice:

Non-Small Cell Lung Carcinoma (NSCLC) Idylla Gene Fusion Test

Gene List: ALK, ROS1, RET, MET exon 14 skipping, NTRK1/2/3

• Medicare (Fully covered) - MBS 73439 - (To determine fusion status of at least ALK, ROS1, RET, NTRK1, NTRK2, and NTRK3)
• Non-Medicare eligible – $675.00
• Medicare (Fully covered) - MBS 73436 - (To determine requirements relating to MET exon 14 skipping status)
• Non-Medicare eligible – $675.00

For non-Medicare eligible patients - Patient Financial Consent Form must be completed.

Fee above is an indication only; please contact testing laboratory for up-to date cost

Please refer to Molecular Genetics - Austin Pathology for specific testing details and request form for ordering, indicating the test required and the biopsy number and date of collection of the sample you wish to be tested.

After this form has been completed, please forward it to the Anatomical Pathology laboratory via the fax number found on the request form.

Biocartis IdyllaTM Gene Fusion assay is an automated mRNA-based real-time PCR closed-cartridge assay for the qualitative detection of specific gene fusions for ALK, ROS1, RET as well as MET exon 14 skipping and 3’-5’ expression imbalance for ALK, ROS1, RET and NTRK1/2/3. This assay is able to detect ALK fusion partners: EML4, KIF5B, HIP1, KLC1, TPR and TFG; ROS1 fusion partners: CD74, SDC4, SLC34A2, EZR, TPM3, GOPC, LRIG3; RET fusion partners: KIF5B, CCDC6.

Note: This assay is newly implemented and is not currently covered under the scope of NATA/RCPA accreditation. The laboratory is actively in the process of seeking accreditation for this test.

• At least 10% tumour nuclei
  
  
• 5μm sections on uncoated slides - 3 sections for resection specimens OR
• 5 sections for small biopsies or resections with very focal tumour OR
• FFPE tissue block 
  
  
• Copy of the histology or cytology report

Contact Molecular Diagnostics - Genetics on 03 9496 5657 to confirm add on suitability